

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer

KEISUKE TAMARI^{1,2}, RYOONG-JIN OH¹, NORIHISA MASAI¹, HIROYA SHIOMI¹,
KEISUKE OTANI², OSAMU SUZUKI² and KAZUHIKO OGAWA²

¹*Miyakojima iGRT Clinic, Osaka, Japan;*

²*Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan*

Reprinted from

ANTICANCER RESEARCH 38: 4207-4212 (2018)

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005
ISSN (online): 1791-7530

Editorial Board

- P. A. ABRAHAMSSON, Malmö, Sweden
B. B. AGGARWAL, Houston, TX, USA
T. AKIMOTO, Kashiwa, Chiba, Japan
P. Z. ANASTASIADIS, Jacksonville, FL, USA
A. ARGIRIS, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
D.-T. BAU, Taichung, Taiwan, ROC
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicetre, France
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
F. T. BOSMAN, Lausanne, Switzerland
M. BOUVET, La Jolla, CA, USA
J. BOYD, Miami, FL, USA
G. BROICH, Monza, Italy
Ø. S. BRULAND, Oslo, Norway
J. M. BUATTI, Iowa City, IA, USA
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
R. CLARKE, Washington, DC, USA
E. DE CLERCQ, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMANDOPOULOS, Boston, MA, USA
L. EGEVAD, Stockholm, Sweden
D. W. FELSHER, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
H. FU, Atlanta, GA, USA
B. FUCHS, Zurich, Switzerland
D. FUCHS, Innsbruck, Austria
D. FUKUMURA, Boston, MA, USA
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
M. GNANT, Vienna, Austria
R. H. GOLDFARB, Guilford, CT, USA
A. HELLAND, Oslo, Norway
L. HELSON, Quakertown, PA, USA
R. HENRIKSSON, Umeå, Sweden
R. M. HOFFMAN, San Diego, CA, USA
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
R. JONES, London, UK
B. KAINA, Mainz, Germany
P. -L. KELLOKUMPU-LEHTINEN, Tampere, Finland
D. G. KIEBACK, Schleswig, Germany
R. KLAPDOR, Hamburg, Germany
H. KOBAYASHI, Bethesda, MD, USA
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
Pat M. KUMAR, Manchester, UK
Shant KUMAR, Manchester, UK
O. D. LAERUM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
S. LINDER, Linköping, Sweden
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umeå, Sweden
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skövde, Sweden
S. S. MARTIN, Baltimore, MD, USA
S. MITRA, Houston, TX, USA
S. MIYAMOTO, Fukuoka, Japan
S. MONCADA, Manchester, UK
M. MUELLER, Villingen-Schwenningen, Germany
F. M. MUGGIA, New York, NY, USA
M. NAMIKI, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J.L. PERSSON, Malmö, Sweden
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATSOUKAS, Norfolk, VA, USA
A. POLLIACK, Jerusalem, Israel
D. RADES, Lübeck, Germany
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELLI, Rome, Italy
S.T. ROSEN, Duarte, CA, USA
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
J. SEHOULI, Berlin, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
A. SLOMINSKI, Birmingham, AL, USA
G.-I. SOMA, Kagawa, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
P. M. UELAND, Bergen, Norway
H. VAN VLIERBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
J. WESTERMARCK, Turku, Finland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Taipei, Taiwan, ROC
M.R.I. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA
G. J. DELINASIOS, Athens, Greece
Managing Editor and
Executive Publisher
J. G. DELINASIOS, Athens, Greece
Managing Editor (1981-2016)

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iiaar-anticancer.org

Managing Editor: editor@iiaar-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IAR is a member of UICC. For more information about ANTICANCER RESEARCH, IAR and the Conferences, please visit the IAR website: www.iiaar-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published bimonthly from January 1981 to December 2008 and monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

Annual Subscription Rates 2018 per volume: Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-37, 1981-2017) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: subscriptions@iiaar-anticancer.org)

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: info@copyright.com.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

D.T.P. BY IAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer

KEISUKE TAMARI^{1,2}, RYOONG-JIN OH¹, NORIHISA MASAI¹, HIROYA SHIOMI¹,
KEISUKE OTANI², OSAMU SUZUKI² and KAZUHIKO OGAWA²

¹Miyakojima iGRT Clinic, Osaka, Japan;

²Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan

Abstract. *Background/Aim:* The long-term efficacy and safety of moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in prostate cancer remains uncertain. This study aimed to evaluate MH-IMRT regimen of 72 Gy in 30 fractions in patients with prostate cancer. *Patients and Methods:* The outcomes of 412 consecutive prostate cancer patients, who received MH-IMRT between May 2007 and December 2012, were retrospectively reviewed. The median patient age was 70.9 (range=50-84) years. Late gastrointestinal (GI) and genitourinary (GU) toxicity rates were evaluated according to the CTCAE ver. 3.0. The overall survival, biochemical relapse-free survival rate (bRFS), late GI toxicity, and GU toxicity rates were analyzed with the Kaplan–Meier method. *Results:* The median follow-up was 71.5 (range, 1.4-124.8) months. The 5-year bRFS rate was 93.2%. The 5-year grade ≥ 2 late GI and GU toxicity rates were 3.3% and 4.5%, respectively. *Conclusion:* MH-IMRT regimen of 72 Gy in 30 fractions was effective and safe for prostate cancer patients.

Prostate cancer is one of the most common cancer types among males, with global incidence and mortality rates in 2012 estimated at 1,100,000 and 307,000 cases, respectively (1). Although lower than in Western countries, the incidence of prostate cancer in Japan continues to increase annually and is expected to be the second most common cancer, after lung cancer, among males until 2020 (2, 3).

External-beam radiotherapy (RT), as well as radical prostatectomy, for localized prostate cancer therapy have been

associated with lower incidences of disease progression and metastases compared with active monitoring (4). The dosages of conventional fractionation, moderate hypofractionation, and extreme hypofractionation are approximately defined as 1.8-2.0, 2.2-4, and >4 Gy, respectively (5). RT with fewer and larger fractions is assumed to be suitable for prostate cancer because the alpha-beta ratio of prostate cancer is relatively lower (approximately 1-3 Gy) than for other cancers (approximately 10 Gy) and the surrounding tissue (*i.e.*, the rectum and bladder) (approximately 3-5 Gy) in a linear-quadratic model (6, 7). In brief, hypofractionated RT (H-RT) might theoretically improve control of prostate cancer and reduce toxicities, as compared with conventional RT (C-RT). A common problem with C-RT at 1.8-2 Gy per fraction is the long treatment duration of approximately 2 months (8, 9). On the other hand, H-RT is more convenient for patients and decreases the costs of treatment (10). Recent studies in Western countries demonstrated that moderately hypofractionated RT (MH-RT) for localized prostate cancer was not less effective or safe than C-RT (5, 11). Based on these promising results, MH-RT presents a viable treatment option for prostate cancer in non-Western populations, including those in East Asia. However, the efficacy and safety of MH-RT for patients in East Asia remain unknown.

Moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) was introduced for patients with prostate cancer in our institution in 2007. At that time, it was rare to treat prostate cancer patients with MH-IMRT in East Asia. The aim of the present study was to retrospectively assess the treatment outcomes of a MH-IMRT regimen of 72 Gy in 30 fractions for the treatment of prostate cancer in an East Asian population.

Materials and Methods

Patient population and pretreatment evaluation. The institutional review board of Miyakojima IGRT Clinic approved the study protocol and all the participants submitted informed consent prior to

Correspondence to: Keisuke Tamari, Miyakojima IGRT Clinic, 1-16-22 Miyakojima Hondori, Miyakojima-ku, Osaka, 534-0021, Japan. Tel: +81 669233501, Fax: +81 669233520, e-mail: tamari@radonc.med.osaka-u.ac.jp

Key Words: Moderately-hypofractionated radiotherapy, intensity-modulated radiotherapy, prostate cancer.

treatment. Between May 2007 and December 2012, 412 patients with prostate cancer were treated with an MH-IMRT regimen of 72 Gy in 30 fractions. Pretreatment evaluation included complete medical history, physical examination, complete blood cell count, biochemical screening profile, prostate-specific antigen (PSA) testing, magnetic resonance imaging, and biopsy. Risk groups were classified according to the clinical practice guidelines of the National Comprehensive Cancer Network (NCCN) (12). Exclusion criteria included lymph node involvement, metastatic disease, any other active malignancy, prior pelvic radiotherapy, and prostatectomy.

Patient characteristics. Patient characteristics are listed in Table I. The median follow-up duration was 71.5 (range, 1.4-124.8) months and the median patient age was 70.9 (range, 50-84) years. According to the NCCN criteria, 41 (10.0%) patients were classified as low-risk, 150 (36.4%) as intermediate-risk, 185 (44.9%) as high-risk, and 36 (8.7%) as very high-risk. Neoadjuvant and adjuvant androgen deprivation therapy (ADT) were delivered to 296 (71.8%) and 190 (46.2%) patients, respectively. Neoadjuvant ADT was delivered to 34.1% of patients with low-risk disease, 51.7% with intermediate-risk, 92.0% with high-risk, and 97.2% with very high-risk disease, and adjuvant ADT was delivered to 14.6%, 21.9%, 66.3%, and 83.3%, respectively. The median duration of neoadjuvant and adjuvant ADT were 5.9 (range, 0.1-96.2) and 18.8 (range, 0.1-103.3) months, respectively.

Treatment. All the patients were evaluated by non-contrast computed tomography (CT) in the supine position using a BrightSpeed™ CT scanner (GE Healthcare, Chicago, IL, USA). Anatomic contouring of the prostate, seminal vesicles, rectum, and bladder was performed. For low-risk patients, the clinical target volume (CTV) was defined as the prostate and for all other patients, the CTV was created by adding a margin of 2 mm in all directions from the prostate and seminal vesicles. The planning target volume (PTV) was generated by adding a margin of 5 mm in all directions other than in the posterior direction, where the margin was 3 mm. For low-risk patients, the radiation dose was 72 Gy in 30 fractions to the PTV of the prostate. For all other patients, the radiation dose was 72 Gy in 30 fractions to the PTV of the prostate and 66 Gy in 30 fractions to the PTV of the seminal vesicles with the simultaneously integrated boost technique. To optimize the dose distribution within the PTV, $V_{107\%} \leq 3\%$ (a volume of at least 3% within PTV should not receive >107% of the prescribed dose) was used along with $D_{95\%} \geq 97\%$ (a volume of $\geq 97\%$ within the PTV can receive a dose that is 95% of the prescribed dose). The rectal dose-volume constraints were $D_{max} \leq 105\%$, $V_{90\%} \leq 8$ cc, $V_{80\%} \leq 10$ cc, $V_{70\%} \leq 13$ cc, and $V_{50\%} \leq 19$ cc. The bladder dose-volume constraints were $D_{max} \leq 105\%$, $V_{90\%} \leq 20\%$, $V_{80\%} \leq 30\%$, and $V_{70\%} \leq 40\%$. Plans were generated with BrainSCAN (ver. 5.31) RT Treatment Planning Software (Brainlab AG, Munich, Germany) with the pencil beam algorithm before November 2010 and thereafter with iPlan RT Dose (ver. 4.1.2) software (Brainlab AG) with the Monte Carlo algorithm. All the patients underwent 8- or 9-field IMRT using a 6-MV linear accelerator (Novalis, Brainlab AG). Daily image guidance was performed. Treatments were performed on consecutive days.

Evaluation of clinical outcomes. In principle, the biochemical response was evaluated according to the PSA level and the incidences of rectal and urinary bleeding every 3 months after treatment. Biochemical failure was assessed using the Phoenix

Table I. Patient characteristics.

Characteristic	Median (range)
Age (years)	70.9 (50-84)
NCCN risk	n (% of total patients)
Low	41 (10.0%)
Intermediate	150 (36.4%)
High	185 (44.9%)
Very high	36 (8.7%)
Initial PSA (ng/ml)	Median (range)
Gleason score	10.23 (0.89-500)
≤ 6	n (% of total patients)
7	95 (23.1%)
8	169 (41.0%)
9	64 (15.5%)
10	75 (18.2%)
T stage	9 (2.2%)
T1c	n (% of total patients)
T2a	108 (26.0%)
T2b	90 (21.6%)
T2c	41 (10.1%)
T3a	64 (16.1%)
T3b	72 (17.3%)
T4	35 (8.4%)
Neoadjuvant ADT	1 (0.2%)
Adjuvant ADT	296 (71.8%)
Median duration of neoadjuvant ADT (months)	190 (46.2%)
Median duration of adjuvant ADT (months)	5.9 (0.1-96.2)
	18.5 (0.1-103.3)

PSA, Prostate-specific antigen; ADT, androgen deprivation therapy; NCCN, National Comprehensive Cancer Network.

Nadir +2 definitions (an increase of ≥ 2 ng/ml above the nadir PSA level) (13). Late gastrointestinal (GI) and genitourinary (GU) toxicities were scored using the Common Terminology Criteria for Adverse Events ver. 3.0 criteria (14). The last visit or date of contact was used to censor surviving patients at the time of analysis.

Statistical analysis. Data analysis was performed using JMP Pro 13 statistical software (SAS Institute Inc., Cary, NC, USA). All the intervals were calculated from the first day of RT. Biochemical relapse-free survival (bRFS), disease-specific survival, overall survival, and late GI and GU toxicity rates were calculated using the Kaplan–Meier method, and groups were using the log–rank test. A probability (*p*) value of <0.05 was considered statistically significant. Statistical tests were based on a two-sided significance level.

Results

Of the 412 patients, 35 experienced biochemical relapse (1 with low-risk disease, 12 with intermediate-risk, 14 with high-risk, and 8 with very high risk). The 5- and 8-year bRFS rates were 93.2% [95% confidence interval (CI)=90.0-95.3%] and 86.1% (95% CI=77.6-91.7%), respectively (Figure 1A). For patients with low-risk, intermediate-risk, high-risk, and




Figure 1. Biochemical relapse-free survival (bRFS). (A) Overall bRFS and (B) bRFS rates stratified by NCCN risk groups. The 5-year actuarial prostate-specific antigen (PSA) relapse-free survival rates were 93.2%, 100%, 93.9%, 93.6%, and 80.3% for all, low-, intermediate-, high-risk, and very high-risk patients, respectively.




Figure 2. Overall survival and disease-specific survival. (A) Overall survival and (B) disease-specific survival. The 5-year actuarial overall survival and disease-specific survival rates were 95.1% and 99.7%, respectively.

very high-risk disease, the 5-year bRFS rates were 100%, 93.9% (95% CI=88.1-96.9%), 93.6% (95% CI=88.5-96.5%), and 80.3% (95% CI=64.0-90.3%), and the 8-year bRFS rates were 90% (95% CI=53.3-98.6%), 81.1% (95% CI=59.6-92.5%), 91.1% (95% CI=85.2-94.8%), and 76.5% (95% CI=59.3-87.8%), respectively. The log-rank test revealed that very high-risk group was statistically significant risk factor for bRFS comparing with other risk groups (vs. low-risk,

$p<0.01$; vs. intermediate-risk, $p=0.01$; vs. high-risk, $p<0.01$). There was no statistical difference between low-, intermediate-, and high-risk groups (Figure 1B). The 5- and 8-year overall survival rates were 95.1% (95% CI=92.3-96.9%) and 90.4% (95% CI=84.8-94.0%), respectively, and the 5- and 8-year disease-specific survival rates were 99.7% (95% CI=98.1-100.0%) and 99.2% (95% CI=96.6-99.8%), respectively (Figure 2A and B). Over the course of the study




Figure 3. Late gastrointestinal (GI) and genitourinary (GU) toxicities. Grade ≥ 2 late GI toxicity (A) and grade ≥ 2 late GU toxicity (B). The 5-year actuarial GI and GU toxicity rates were 3.3% and 4.5%, respectively.

period, 29 (7.0%) patients died, including 2 (4.9%) who died from progression of prostate cancer. These 2 patients experienced biochemical relapse at 11.8 and 45.9 months, and died at 28.1 and 73.4 months after RT, respectively.

In total, 33 (8.0%), 8 (1.9%), and 4 (1.0%) patients developed grades 1, 2, and 3 GI toxicities, respectively. The patients with grade 3 GI toxicity experienced rectal bleeding, which required endoscopic ablation at 13.9, 15.7, 17.8, and 55.6 months after RT, respectively. No patient experienced grade ≥ 4 GI toxicity. The 5- and 8-year \geq grade 2 late GI toxicity rates were 3.3% (95% CI=1.9-5.8%) and 3.3% (95% CI=1.9-5.8%), respectively (Figure 3A). In total, 12 (2.9%), 19 (4.6%), and 6 (1.4%) patients developed grade 1, 2, and 3 GU toxicity, respectively. All the patients with grade 3 GU toxicity experienced bleeding from the bladder, that required endoscopic ablation at 3.7, 16.6, 54.4, 61.5, 73.8, and 92.8 months after RT, respectively. No patient experienced grade ≥ 4 GU toxicity. The 5- and 8-year grade ≥ 2 late GU toxicity rates were 4.5% (95% CI=2.8-7.1%) and 9.9% (95% CI=5.7-16.6%), respectively (Figure 3B).

Discussion

Over the last 2 years, several large phase 3 studies were conducted in Western countries to determine whether MH-RT is inferior to C-RT (Table II). According to these results, MH-RT is now an emerging strategy for the treatment of prostate cancer.

The PROFIT trial randomized 1,206 intermediate-risk prostate cancer patients to 78 Gy in 39 fractions over 7.8 weeks (C-RT) or 60 Gy in 20 fractions over 4 weeks (MH-

RT). After a median follow-up of 6 years, the 5-year bRFS rates for the C-RT and MH-RT groups were both 85%, late grade ≥ 2 GI toxicity rates were 11% and 7%, and grade ≥ 2 GU toxicity rates were 19% and 20%, respectively. This study concluded MH-RT was not inferior to C-RT (15). The CHHiP trial randomized 3,216 predominantly intermediate-risk prostate cancer patients to 74 Gy in 37 fractions over 7.4 weeks (C-RT), 60 Gy in 20 fractions over 4 weeks (MH-RT1), or 57 Gy in 19 fractions over 3.8 weeks (MH-RT2). After a median follow-up of 5.2 years, the 5-year bRFS rates were 88.3%, 90.6%, and 85.9%, the late grade ≥ 2 GI toxicity rates were 13.7%, 11.9%, and 11.3%, and the grade ≥ 2 GU rates were 9.1%, 11.7%, and 9.6% in the C-RT, MH-RT1, and MH-RT2 groups, respectively. This study concluded MH-RT1 that only was not inferior to C-RT (16). The RTOG0415 trial randomized 1,115 low-risk prostate cancer patients to 73.8 Gy in 41 fractions over 8.2 weeks (C-RT) or 70 Gy in 28 fractions over 5.6 weeks (MH-RT). After a median follow-up of 5.8 years, the 5-year bRFS rates were 85.3% and 86.3%, the late grade ≥ 2 GI toxicity rates were 14% and 22%, and the grade ≥ 2 GU toxicity rates were 19% and 23% in the C-RT and MH-RT groups, respectively. This study concluded that despite the increased adverse events in H-RT-treated patients, MH-RT was not inferior to C-RT (17). The Dutch HYPRO trial randomized 820 predominantly high-risk prostate cancer patients to 78 Gy in 39 fractions over 7.8 weeks (C-RT) or 64.6 Gy in 19 fractions over 6.3 weeks (3 days a week, MH-RT). After a median follow-up of 5 years, the 5-year bRFS rates were 77.1% and 80.5%, the 3-year late grade ≥ 2 GI toxicity rates were 17.7% and 21.9%, and the grade

Table II. Summary of published studies reporting treatment outcomes of hypofractionated RT for prostate cancer.

Study	RT technique	Follow-up (median)	Risk group	Arm	5-year bRFS	Late GI \geq G2	Late GU \geq G2
PROFIT (15)	IMRT or 3D-CRT	6 years	Intermediate	78 Gy/39 Fx 60 Gy/20 Fx	85% 85%	11% 7%	19% 20%
CHHiP (16)	IMRT	5.2 years	Mainly intermediate	74 Gy/37 Fx 60 Gy/20 Fx 57 Gy/19 Fx	88.3% 90.6% 85.9%	13.7% 11.9% 11.3%	9.1% 11.7% 6.6%
RTOG0415 (17)	IMRT or 3D-CRT	5.8 years	Low	73.8Gy/41 Fx 70 Gy/28 Fx	85.3% 86.3%	14% 22%	23% 30%
Dutch HYPRO (18-19)	IMRT or 3D-CRT	5 years	Mainly high	78 Gy/39 Fx 64.6 Gy/19 Fx*	77.1% 80.5%	17.7% 21.9%	39.0% 41.3%
MDACC (20)	IMRT	6 years	Mainly intermediate	75.6 Gy/42 Fx 72 Gy/30 Fx	Not reported	5.1% 10.0%	16.5% 15.8%
Present study	IMRT	6 years	Mainly intermediate and high	72 Gy/30Fx	93.2%	3.3%	4.5%

RT, Radiation therapy; bRFS, biochemical relapse-free survival; GI, gastrointestinal toxicity; GU, genitourinary toxicity; IMRT, intensity-modulated radiation therapy; 3D-CRT, three dimensional-conformal radiation therapy; Fx, fractions. *3 days a week.

\geq 2 GU toxicity rates were 39.0% and 41.3% in the C-RT and MH-RT groups, respectively. These studies concluded MH-RT was not superior to C-RT, neither in terms of 5-year bRFS nor in terms of late GU and GI toxicities (18, 19). The MDACC trial randomized 203 predominantly intermediate-risk prostate cancer patients to 75.6 Gy in 42 fractions over 8.4 weeks (C-RT) or 72 Gy in 30 fractions over 6 weeks (MH-RT). After a median follow-up of 6 years, the late grade \geq 2 GI toxicity rates were 16.5% and 15.8%, and the grade \geq 2 GU toxicity rates were 5.1% and 10.0% in the C-RT and MH-RT groups, respectively. This study is ongoing (20). Taken together, the 5-year bRFSs rates ranged from 80.6% to 90.5% in the MH-RT arms. In our study, the overall 5-year bRFS rate was 93.2%. Given that our patients predominantly had intermediate- and high-risk disease, the results of this retrospective analysis were satisfactory. In addition, the rate of late GI and GU toxicities in our patients were relatively lower than in previous studies. In our study, the 5-year late grade \geq 2 GI and GU toxicity rates were 3.3% and 4.5%, while previous studies reported rates of 7%-22% and 5.2%-39%, respectively. A possible reason for the high rate of late toxicities in previous studies seemed to be the radiation technique. In brief, several randomized studies, including the PROFIT, RTOG0415, and HYPRO trials, permitted IMRT and three dimensional-conformal radiation therapy (3D-CRT), while the CHHiP and MDACC trials permitted only IMRT. Thus, MH-IMRT for prostate cancer might be better than 3D-CRT. Finally, at least a 10-year follow-up should be considered after HF-IMRT, since late GU toxicity was more frequently encountered by long-term follow-up, as compared with late GI toxicity.

Conclusion

An MH-IMRT regimen of 72 Gy in 30 fractions effectively controlled the disease with acceptable toxicities in the studied cohort of East Asian prostate cancer patients.

References

- 1 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: <http://globocan.iarc.fr>, accessed on 10/05/2018.
- 2 Ito K, Kakehi Y, Naito S, Okuyama A, and Japanese Urological Association: Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. *Int J Urol* 15: 763-768, 2008.
- 3 Ito K: Prostate cancer in Asian men. *Nat Rev Urol* 11: 197-212, 2014.
- 4 Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E and Neal DE: 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. *N Engl J Med* 375: 1415-1424, 2016.
- 5 Höcht S, Aebbersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, Hölscher T, Martin T, Sedlmayer F, Wenz F, Zips D and Wiegel T: Hypofractionated radiotherapy for localized prostate cancer. *Strahlentherapie Onkol* 193: 1-12, 2017.
- 6 Hegemann NS, Guckenberger M, Belka C, Ganswindt U, Manapov F, Li M: Hypofractionated radiotherapy for prostate cancer. *Radiat Oncol* 9: 275, 2014.

- 7 Brenner DJ and Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. *Int J Radiat Oncol Biol Phys* 43: 1095-1101, 1999.
- 8 Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK and Pollack A: Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer. *Int J Radiat Oncol Biol Phys* 70: 67-74, 2008.
- 9 Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, Aird EG, Bottomley D, Huddart RA, Jose CC, Matthews JHL, Millar JL, Murphy C, Russell JM, Scrase CD, Parmar MKB and Sydes MR: Escalated-dose *versus* control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial. *Lancet Oncol* 15: 464-473, 2014.
- 10 Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, Godby J, Choi S, Lee AK, Schlembach PJ, Frank SJ, McGuire SE and Hoffman KE: Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. *Adv Radiat Oncol* 2: 249-258, 2017.
- 11 Datta NR, Stutz E, Rogers S and Bodis S: Conventional *versus* hypofractionated radiation therapy for localized or locally advanced prostate cancer: a systematic review and meta-analysis along with therapeutic implications. *Int J Radiat Oncol Biol Phys* 99: 573-589, 2017.
- 12 National Comprehensive Cancer Network. Prostate Cancer, Version 2.2017. [cited 2018 Mar 20] Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
- 13 Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH and Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys* 65: 965-974, 2006.
- 14 Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol* 13: 176-181, 2003.
- 15 Catton CN, Lukka H, Gu C-S, Martin JM, Supiot S, Chung PWM, Bauman GS, Bahary J-P, Ahmed S, Cheung P, Tai H, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C, Dayes IS, Warde P, Craig TK, Julian JA and Levine MN: Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. *J Clin Oncol* 35: 1884-1890, 2017.
- 16 Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C and Hall E: Conventional *versus* hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. *Lancet Oncol* 17: 1047-1060, 2016.
- 17 Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R and Sandler HM: Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. *J Clin Oncol* 34: 2325-2332, 2016.
- 18 Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H de, Heemsbergen W, Heijmen B and Pos F: Hypofractionated *versus* conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol* 17: 1061-1069, 2016.
- 19 Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B and Incrocci L: Hypofractionated *versus* conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. *Lancet Oncol* 17: 464-474, 2016.
- 20 Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE and Kuban DA: Risk of Late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial. *Int J Radiat Oncol Biol Phys* 88: 1074-1084, 2014.

Received April 11, 2018

Revised May 19, 2018

Accepted May 30, 2018

Instructions for Authors 2018

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2018 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.